Amarin Corporation plc (ADR) (AMRN) EPS Estimated At $-0.05

October 7, 2017 - By Vivian Park

 Amarin Corporation plc (ADR) (AMRN) EPS Estimated At $ 0.05
Investors sentiment decreased to 1.03 in Q2 2017. Its down 0.21, from 1.24 in 2017Q1. It dropped, as 10 investors sold Amarin Corporation plc (ADR) shares while 27 reduced holdings. 16 funds opened positions while 22 raised stakes. 100.78 million shares or 1.09% less from 101.89 million shares in 2017Q1 were reported.
Raymond James Svcs Advisors has invested 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Clearbridge Ltd has invested 0.35% in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Michigan-based Asset Mgmt Incorporated has invested 0% in Amarin Corporation plc (ADR) (NASDAQ:AMRN). D E Shaw & holds 0% or 28,811 shares. Lpl Lc stated it has 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Cambridge Research Advsrs has 0% invested in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 17,336 shares. California Public Employees Retirement Systems invested 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN). Carl Domino holds 0.46% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 98,000 shares. State Of New Jersey Common Pension Fund D holds 0% or 187,000 shares in its portfolio. Northwestern Mutual Wealth holds 0% or 200 shares in its portfolio. Cetera Advsr Limited Liability reported 12,020 shares. Proshare Advsr Ltd Liability Co invested in 0.01% or 135,234 shares. Moreover, Creative Planning has 0% invested in Amarin Corporation plc (ADR) (NASDAQ:AMRN). 540 are owned by Hanson And Doremus Management. Mariner Wealth Advsrs Ltd Limited Liability Company holds 0.02% in Amarin Corporation plc (ADR) (NASDAQ:AMRN) or 104,984 shares.

Investors wait Amarin Corporation plc (ADR) (NASDAQ:AMRN) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.05 earnings per share, up $0.05 or 50.00 % from last year’s $-0.1 same quarter earnings. Amarin Corporation plc (ADR)’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.05 EPS reproted in the previous quarter, The stock increased 1.15% or $0.04 on October 6, reaching $3.51. About 837,349 shares traded. Amarin Corporation plc (ADR) (NASDAQ:AMRN) has risen 76.19% since October 8, 2016 and is uptrending. It has outperformed by 59.49% the S&P500.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) Ratings Coverage

Among 4 analysts covering Amarin Corp (NASDAQ:AMRN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amarin Corp had 11 analyst reports since May 12, 2016 according to SRatingsIntel. As per Monday, June 12, the company rating was maintained by Cantor Fitzgerald. The stock of Amarin Corporation plc (ADR) (NASDAQ:AMRN) has “Buy” rating given on Monday, June 26 by Cantor Fitzgerald. H.C. Wainwright maintained the shares of AMRN in report on Tuesday, June 27 with “Buy” rating. Jefferies initiated it with “Buy” rating and $3.50 target in Thursday, May 12 report. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, August 14. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, June 1 report. The company was maintained on Thursday, August 3 by H.C. Wainwright. Cantor Fitzgerald initiated Amarin Corporation plc (ADR) (NASDAQ:AMRN) rating on Wednesday, October 5. Cantor Fitzgerald has “Buy” rating and $6 target. Jefferies maintained Amarin Corporation plc (ADR) (NASDAQ:AMRN) rating on Monday, June 12. Jefferies has “Buy” rating and $500 target. The stock of Amarin Corporation plc (ADR) (NASDAQ:AMRN) earned “Buy” rating by Cantor Fitzgerald on Tuesday, August 29.

Amarin Corporation plc is a biopharmaceutical firm with activities in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The company has market cap of $961.44 million. The Firm operates through the development and commercialization of Vascepa segment. It currently has negative earnings. The Company’s lead product, Vascepa capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By :